MedTrace Logo

Clinical Pharmacology of MDA [3,4-methylenedioxyamphetamine]

NCT00823407 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-05-31

No results posted yet for this study

Summary

The purpose of this study is to investigate the pharmacological and cognitive effects of MDA in healthy humans.

Conditions

  • Healthy

Interventions

DRUG

MDA

subjects will receive a single oral dose of MDA 98mg/70kg body weight

DRUG

Placebo

Subjects will receive a single oral dose of placebo

Sponsors & Collaborators

Principal Investigators

  • John E Mendelson, MD · CPMC Research Institute

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-01-31
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00823407 on ClinicalTrials.gov